martin palazzo

bio & engineering

[martin palazzo @boardsofdata]

Molecular biology 🧬 wet lab iteration for cell therapies implies intense R&D resources.

By leveraging AI, computational biology algorithms and multi-omics assay data @StammBio presents MoNA: a cell representation atlas designed to accelerate bio-innovation cycles. Take a look👇

[Stämm @StammBio]

1/ 🚨 Uncertainty in cell & gene therapy development? Enter MoNA: our Multi-Omic Network Atlas technology!

[martin palazzo @boardsofdata]

@Corneliodelp Ññ

[Simone Conradi @S_Conradi]

Eigenvalues of random matrices
Made with #python #numpy #matplotlib and #marimo

[Simone Conradi @S_Conradi]

Made with #python #numpy #matplotlib and #marimo (and also #wigglystuff)

[martin palazzo @boardsofdata]

The @StammBio 's High Throughput Bioprocessor (HTB) is alive 🚀🧬: the live demo at BioUSA 2026 shows how the HTB automates a bubble-free laminar flow continuous biomanufacturing operation. Take a look at https://t.co/jVrWIBx1lT

[Stämm @StammBio]

At Booth 5735, Juan Martín Cabaleiro, PhD (our CTO), is running the HTB live, walking visitors through a full demo from cold start to continuous perfusion.

View the whole demo here: https://t.co/Ez8UiDtE8j

#BIO2026

[Stämm @StammBio]

Five years of mechanical engineering, machine learning, and a team in Buenos Aires went into the machine running behind Jean-Christophe Quillet at BIO 2026.

#BIO2026

[Stämm @StammBio]

Bubble-free laminar flow. Multiple independent processes. Simultaneous production. No impellers, no spargers, no shear damage to your cells. Continuous harvesting. The real thing on a benchtop.

We have four days and one machine. If you want a demo, book ahead.

[Stämm @StammBio]

If you work in bioprocess development, cell therapy, or biologics manufacturing, and you've been wondering what continuous, laminar flow-based, shear stress-free bioprocessing actually looks like in practice, this is your chance to see it running.

[Stämm @StammBio]

We're bringing something new to BIO International Convention 2026.

Juan Martin Cabaleiro, Subhadeep Das, Faith Wallace-Gadsden, and Jean-Christophe Quillet will be there representing Stämm and running the first public demos of the HTB: our High-Throughput Bioprocessor live.

[martin palazzo @boardsofdata]

Julio Le Parc

[martin palazzo @boardsofdata]

Julio Le Parc

[martin palazzo @boardsofdata]

Julio Le Parc

[Mahdi E Kahou @MahdiKahou]

Recently, I was teaching the Law of Large Numbers and diversification, so I decided to share this illustration here.
As you average more and more independent, identically noisy copies of an image, the noise cancels out and the original emerges.
Code in the comments.

[GaboAir @GaboAir]

Llegando a Buenos Aires (Aeroparque) desde el Norte.

📹 Aterrizaje en velocidad y sonido reales.

[El Gato y La Caja @ElGatoyLaCaja]

Hoy es un día importante.

Stämm, una startup BIO argentina de deep tech, acaba de traer un pedazo de futuro al presente.

Hoy se festeja. 🇦🇷🌱

[martin palazzo @boardsofdata]

Amazing news: The @StammBio 's High Throughput Bioprocessor is alive 🧬🧬🧬 .

The automated platform based on continuous laminar flow microfluidics changes the game in scaling bio-manufacturing. Take a look 👇

[Stämm @StammBio]

We’re redefining biomanufacturing. Today, we introduce the High-Throughput Bioprocessor (HTB), Stämm’s new automated platform to rethink biological scaling.

[Stämm @StammBio]

We’re redefining biomanufacturing. Today, we introduce the High-Throughput Bioprocessor (HTB), Stämm’s new automated platform to rethink biological scaling.

[Tomás G. @tomasgna]

my (first!) article, “From the virtual community to ‘Trust and Safety’: eBay (1995–2007) and the rise of platform governance” is out on Big Data & Society! it is a history of content moderation at eBay, where they coined the term Trust and Safety 🌐 link below

[will brown @willcb]

can confirm these are the vibes

if you’re questioning whether staying in academia, quant, big tech, or a big lab is how you want to spend the singularity, hit me up

[Stämm @StammBio]

For decades in the biopharmaceutical industry, bigger was better: massive tanks, sprawling facilities, global blockbusters. But rising biosimilar competition and demand for specialized therapies are forcing a shift. The old batch paradigm is giving way to a new way.

[Eryney @eryney_ok]

Never been a better time to pivot into biology.

The problems are very far from solved. Engineering skills will be extremely important in continuing to push the frontier forward. It's hard, but wildly worthwhile.

Leave B2B SaaS to agents :)